Skip to content

Cogent Biosciences

US · COGT #2052 by market cap Listed 2016
26.72 -1.03 -3.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:53

Price chart

Pre-market 27.40 -1.23%
After-hours 27.20 +1.82%
Overnight 27.51 -0.83%
42.8426.7226.722026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on COGT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -23.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 10.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -448.3% Better than 4%
Net margin -2,276.8% Better than 2%
Return on equity -95.0% Better than 6%
Return on invested capital -71.8% Better than 4%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -27.3% Better than 20%
6-month return -18.2% Better than 29%
12-month return (ex latest month) -15.1% Better than 19%
Distance below 52-week high 38.9% Better than 30%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 14.2x Better than 96%
Debt to assets 25.5% Better than 48%
Interest coverage -106.4x Better than 5%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 107.0% Better than 85%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.46%
1M -14.48%
3M -24.34%
6M -18.86%
YTD -24.79%
1Y -23.01%
3Y +254.78%
5Y +172.60%

Key statistics

Price & volume

Prev close
27.74
Open
27.26
Day range
26.62 - 27.83
Avg price
27.00
Volume
2.13M
Turnover
57.48M
Amplitude
4.36%
52-week range
26.36 - 43.73

Valuation

P/E
-12.37
P/E (TTM)
-11.82
P/B
10.29
EPS
-2.16
Net profit
-375.83M
Net assets
451.52M

Share structure

Market cap
4.65B
Float cap
4.62B
Shares out
173.99M
Float shares
172.99M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-09-26
52-week range 2% of range
26.36 43.73

38.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-32.13M net over the window

Short interest

Shares short
17.42M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Cogent Biosciences (COGT)?

Cogent Biosciences last traded at 26.72. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Cogent Biosciences's market cap?

About 4.65B.

What is the P/E ratio of Cogent Biosciences?

The trailing twelve-month P/E is -11.82. The Valuation tab shows it against the stock's own five-year range.

Does Cogent Biosciences pay a dividend?

Cogent Biosciences does not currently pay a regular dividend.

Is Cogent Biosciences a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 55.29, which implies 107.0% upside from the current price. This is not investment advice.

What is Cogent Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Cogent Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:53:23 · For reference only, not investment advice and not tailored to your situation.

Cogent Biosciences discussion 0 comments

Add a comment